LENVIMA® (lenvatinib) is a prescription medicine that is used to treat people with certain kinds of cancer.
LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing.
LENVIMA is used along with another medicine called everolimus to treat adults with a type of kidney cancer called advanced renal cell carcinoma (RCC) after one course of treatment with another anti-cancer medicine.
LENVIMA is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgery.
LENVIMA is used along with another medicine called pembrolizumab to treat advanced endometrial carcinoma, a type of uterine cancer:
that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and
that has progressed after treatment with anti-cancer medicine, and
that cannot be treated with surgery or radiation.
This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
It is not known if LENVIMA is safe and effective in children.